Acute effects of metformin therapy include improvement of insulin resistance and ovarian morphology

Fertility and Sterility

Volumn 87, Issue 4, 2007, Pages 870-875

  Bayrak, Aykut ^a   Terbell, Heather ^a   Urwitz Lane, Rebecca ^a   Mor, Eliran ^a   Stanczyk, Frank Z ^a   Paulson, Richard J ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

anti M llerian hormone; antral follicle count; inhibin B; ovarian morphology; Polycystic ovary syndrome (PCOS)

Indexed keywords

FOLLITROPIN; GLUCOSE; INHIBIN B; INSULIN; LUTEINIZING HORMONE; METFORMIN; MUELLERIAN INHIBITING FACTOR; TESTOSTERONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LOW DRUG DOSE; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL;

ADULT; FEMALE; FOLLICLE STIMULATING HORMONE; GLYCOPROTEINS; HUMANS; HYPOGLYCEMIC AGENTS; INHIBINS; INSULIN RESISTANCE; LUTEINIZING HORMONE; METFORMIN; OVARIAN FOLLICLE; OVARY; POLYCYSTIC OVARY SYNDROME; PROSPECTIVE STUDIES; TESTICULAR HORMONES; TESTOSTERONE;

EID: 34047244538     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2006.08.096     Document Type: Article

References (36)

1. Knochenhaur E.S., Key T.J., Kahsar-Miller M., Waggoner W., Boots L.R., and Azziz R. Prevalence of polycystic ovary syndrome in unselected black and white women of the southeastern United States. J Clin Endocrinol Metab 83 (1998) 3078-3082
2. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term risks related to polycystic ovary syndrome. Fertil Steril 81 (2004) 19-25
3. Dunaif A., Segal K.R., Futterweit W., and Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38 (1989) 1165-1174
4. Ovalle F., and Azziz R. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril 77 (2002) 1095-1105
5. Mor E., Zograbyan A., Saadat P., Bayrak A., Tourgeman D.E., Zhang C., et al. The insulin resistant subphenotype of polycystic ovary syndrome: clinical parameters and pathogenesis. Am J Obstet Gynecol 190 (2004) 1654-1660
6. Burghen G.A., Givens J.R., and Kitabchi A.E. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovary disease. J Clin Endocrinol Metab 50 (1980) 113-116
7. Velasquez E.M., Mendoza S., Hamer T., Sosa F., and Glueck C.J. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 43 (1994) 647-654
8. Nestler J.E., Jakubowicz D.J., Evans W.S., and Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 338 (1998) 1876-1880
9. Moghetti P., Castello R., Negri C., Tosi F., Perrone F., Caputo M., et al. Metformin effects on clinical features, endocrine and metabolic profiles and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 85 (2000) 139-146
10. Baillargeon J.P., Jakubowicz D.J., Luorno M.J., Jakubowicz S., and Nestler J.E. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril 82 (2004) 893-902
11. Garber A.J., Duncan T.G., Goodman A.M., Mills D.J., and Rohlf J.L. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 103 (1997) 491-497
12. Nestler J.E., Stovall D., Akhter N., Luorno M.J., and Jakubowicz D.J. Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome. Fertil Steril 77 (2002) 209-215
13. Durlinger A.L., Kramer P., Karels B., de Jong F.H., Uilenbroek J.T., Grootegoed A., et al. Control of primordial follicle recruitment by anti-Mullerian hormone in the mouse ovary. Endocrinology 140 (1999) 5789-5796
14. Durlinger A.L., Gruijters M.J., Kramer P., Karels B., Ingraham H.A., Nachtigal M.W., et al. Anti-Mullerian hormone inhibits initiation of primordial follicle growth in the mouse ovary. Endocrinology 143 (2002) 1076-1084
15. McGee E.A., Smith R., Spears N., Nachtigal M.W., Ingraham H., and Hsueh A.J. Mullerian inhibitory substance induces growth of rat preantral ovarian follicles. Biol Reprod 64 (2001) 293-298
16. de Vet A., Laven J.S., de Jong F.H., Themmen A.P., and Fauser B.C. Antimullerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril 77 (2002) 357-362
17. van Rooij I.A., Broekmans F.J., te Velde E.R., Fauser B.C., Bancsi L.F., de Jong F.H., and Themmen A.P. Serum anti-Mullerian hormone levels: a novel measure of ovarian reserve. Hum Reprod 17 (2002) 3065-3071
18. Fanchin R., Schonauer L.M., Righini C., Guibourdenche J., Frydman R., and Taieb J. Serun anti-Mullerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Hum Reprod 18 (2003) 323-327
19. Hazout A., Bouchard P., Seifer D.B., Aussage P., Junca A.M., and Cohen-Bacrie P. Serum antimullerian hormone/Mullerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertil Steril 82 (2004) 1323-1329
20. La Marca A., Orvieto R., Giulini S., Jasonni V.M., Volpe A., and De Leo V. Mullerian-inhibiting substance in women with polycystic ovary syndrome: relationship with hormonal and metabolic characteristics. Fertil Steril 82 (2004) 970-972
21. Fleming R., Harborne L., MacLaughlin D.T., Ling D., Norman J., Sattar N., et al. Metformin reduces serum Mullerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment. Fertil Steril 83 (2005) 130-136
22. Fallat M.E., Siow Y., Marra M., Cook X., and Carillo A. Mullerian-inhibiting substance in follicular fluid and serum: a comparison of patients with tubal factor infertility, polycystic ovary syndrome, and endometriosis. Fertil Steril 67 (1997) 962-965
23. Cook C.L., Siow Y., Brenner A.G., and Fallat M.E. Relationship between serum Mullerian-inhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women. Fertil Steril 77 (2002) 141-146
24. Pigny P., Merlen E., Robert Y., Cortet-Rudelli C., Decanter C., Jonard S., et al. Elevated serum level of anti-Mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab 88 (2003) 5957-5962
25. Ueno S., Kuroda T., Maclaughlin D.T., Ragin R.C., Manganaro T.F., and Donahoe P.K. Mullerian inhibiting substance in the adult rat ovary during various stages of the estrous cycle. Endocrinology 125 (1989) 1060-1066
26. Ueno S., Takahashi M., Manganaro T.F., Ragin R.C., and Donahoe P.K. Cellular localization of Mullerian inhibiting substance in the developing rat ovary. Endocrinology 124 (1989) 1000-1006
27. Groome N.P., Illingworth P.J., O'Brien M., and Pai R. Measurement of dimeric inhibin B throughout the human menstrual cycle. J Clin Endocrinol Metab 81 (1996) 1401-1405
28. Falcone T., Billiar R., and Morris D. Serum inhibin levels in polycystic ovary syndrome: effect of insulin resistance and insulin secretion. Obstet Gynecol 78 (1991) 171-175
29. Anderson R.A., Groome N.P., and Baird D.T. Inhibin A and inhibin B in women with polycystic ovarian syndrome during treatment with FSH to induce mono-ovulation. Clin Endocrinol 48 (1998) 577-584
30. Lockwood G.M., Muttukrishna S., Groome N.P., Matthews D.R., and Ledger W.L. Mid-follicular phase pulses of inhibin B are absent in polycystic ovarian syndrome and are initiated by successful laparoscopic ovarian diathermy: a possible mechanism regulating emergence of the dominant follicle. J Clin Endocrinol Metab 83 (1998) 1730-1735
31. Laven J.S., Imani B., Eijkemans M.J., de Jong F.H., and Fauser B.C. Absent biologically relevant associations between serum inhibin B concentrations and characteristics of polycystic ovary syndrome in normogonadotropic anovulatory infertility. Hum Reprod 16 (2001) 1359-1364
32. Cortet-Rudelli C., Pigny P., Decanter C., Leroy M., Maunoury-Lefebvre C., Thomas-Desrousseaux P., et al. Obesity and serum luteinizing hormone level have an independent and opposite effect on the serum inhibin B level in patients with polycystic ovary syndrome. Fertil Steril 77 (2002) 281-287
33. Pigny P., Cortet-Rudelli C., Decanter C., Deroubaix D., Soudan B., Duhamel A., et al. Serum levels of inhibins are differentially altered in patients with polycystic ovary syndrome: effects of being overweight and relevance to hyperandrogenism. Fertil Steril 73 (2000) 972-977
34. Welt C.K., Taylor A.E., Martin K.A., and Hall J.E. Serum inhibin B in polycystic ovary syndrome: regulation by insulin and luteinizing hormone. J Clin Endocrinol Metab 87 (2002) 5559-5565
35. Elting M.W., Kwee J., Schats R., Rekers-Mombarg L.T., and Schoemaker J. The rise of estradiol and inhibin B after acute stimulation with follicle-stimulating hormone predict follicle cohort size in women with polycystic ovary syndrome, regularly menstruating women with polycystic ovaries, and regularly menstruating women with normal ovaries. J Clin Endocrinol Metab 86 (2001) 1589-1595
36. Magoffin D.A., and Jakimiuk A.J. Inhibin A, inhibin B and activin A in the follicular fluid of regularly cycling women. Hum Reprod 12 (1997) 1714-1719